{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-025075","form_type":"8-K","ticker":"ABSI","cik":"0001672688","company_name":"Absci Corp","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.288407+00:00","generated_at":"2026-05-21T16:26:35.480888+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Absci starts Phase 1 dosing for ABS-101; Q1 net loss $26.3M, cash into H1 2027","bullets":["Initiated dosing in first-in-human Phase 1 study of ABS-101 (anti-TL1A); interim data expected H2 2025.","ABS-201 NHP data show extended half-life and >90% subcutaneous bioavailability; Phase 1 start targeted early 2026.","Q1 2025 revenue $1.2M (up from $0.9M YoY); net loss $26.3M vs $22.0M; R&D spending rose to $16.4M.","Cash, equivalents, and short-term investments of $134.0M sufficient to fund operations into first half of 2027.","Company expects to sign one or more new partnerships, including with a large pharma, in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-025075","json":"https://secwatch.observer/filing/0001628280-25-025075.json","markdown":"https://secwatch.observer/filing/0001628280-25-025075.md","text":"https://secwatch.observer/filing/0001628280-25-025075.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1672688/000162828025025075/0001628280-25-025075-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1672688/000162828025025075/absc-20250513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T16:26:35.480888+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}